Chronic heart failure is far more than a problem of a failing pump. The condition disrupts the delicate interplay between the heart and the lungs, producing pulmonary congestion, altered gas exchange, and impaired lung mechanics. As a result, the work and energy cost of every breath rises, and even modest physical effort becomes exhausting. This physiological burden explains why patients with heart failure often experience profound breathlessness and fatigue, and why rehabilitation programs that target only the legs and arms may miss a crucial piece of the therapeutic puzzle. The Bialystok team designed their intervention with this cardiopulmonary coupling in mind, pairing conventional endurance training with structured breathing exercises and inspiratory muscle training.

The evidence base for exercise training in heart failure is already strong. Large randomized trials and meta-analyses have shown that regular exercise improves physical endurance and quality of life, reduces all-cause and heart failure-related hospitalizations, and may even lower long-term mortality. The European Society of Cardiology currently recommends supervised exercise training and rehabilitation for all patients with chronic heart failure who are able to participate. Yet in practice, cardiac rehabilitation remains dramatically underused, with participation rates estimated at only 10 to 30 percent. Distance, cost, frailty, and simple logistics keep many patients from ever setting foot in a center-based program, creating an urgent need for models that work beyond the clinic walls.

To test whether rehabilitation could be safely and effectively moved into patients’ homes, the researchers enrolled 63 patients with stable heart failure with reduced ejection fraction, meaning their hearts pumped at less than 40 percent of normal capacity. Participants were randomized in a 3:2 ratio to an intervention or control group. The intervention group received detailed instruction in a tailored home program: physical training performed once daily, at least five times per week, at an intensity of 4 to 5 points on a 10-point Borg scale of perceived exertion, building toward sessions of 45 to 60 minutes. Each patient also received a Pulmogain RespiTrain device for resistance training of the respiratory muscles, along with an illustrated booklet, a pedometer, and a self-monitoring diary to record heart rate, blood pressure, breathlessness, and step counts.

Crucially, the program did not abandon patients to their own devices. Scheduled clinic visits at one and three months allowed the team to verify exercise technique and adjust the training plan, while weekly telephone support reinforced adherence. Family members or caregivers were trained to supervise sessions at home. This hybrid of autonomy and remote oversight proved remarkably effective: adherence to the recommended protocol, defined as completing at least 120 sessions over 24 weeks, averaged an impressive 91.5 percent, and 82.8 percent of patients who started the program completed the full six-month assessment. Patients logged an average of more than 9,000 steps per day, including roughly 3,300 steps within each dedicated training session.

The physiological results were striking. After six months, the distance patients could walk in six minutes, a standard measure of functional capacity, increased by an average of 37.86 meters, a change the authors describe as clinically meaningful. Maximal inspiratory pressure, the force the diaphragm and other inspiratory muscles can generate, rose by 20.21 centimeters of water, while maximal expiratory pressure climbed by 20.75 centimeters of water, both highly statistically significant gains. Fatigue, measured with the validated Fatigue Severity Scale, fell by an average of 0.68 points. Notably, the magnitude of the inspiratory pressure improvement closely matches results from meta-analyses of supervised inspiratory muscle training, which reported gains of roughly 16 to 25 centimeters of water, suggesting that home-based delivery can achieve comparable physiological effects.

The respiratory component of the program deserves particular attention. Heart failure impairs ventilation and the matching of airflow to blood perfusion in the lungs, and previous research has shown that breathing exercises and inspiratory muscle training can improve not only respiratory mechanics but also exercise tolerance and quality of life. Meta-analytic data indicate that patients with inspiratory muscle weakness benefit most from this form of training, and the baseline inspiratory pressure of the Bialystok cohort, around 63 centimeters of water, was consistent with substantial respiratory muscle impairment. The study’s combined approach, pairing endurance walking with targeted respiratory resistance training, produced gains consistent with the best results reported in the supervised literature.

Safety, often the central concern when prescribing unsupervised exercise to cardiac patients, was reassuring. No serious adverse events related to training were reported, and no deaths occurred in the heart failure group. The few exercise-related complaints were minor: one case each of excessive fatigue, breathlessness, and calf cramps, and two episodes of chest pain. The researchers attribute this safety profile to careful patient selection, thorough instruction in contraindications and safe exercise principles, and the structured self-monitoring system that kept the study team informed of each patient’s status week by week.

The study was not without limitations, and the authors are candid about them. The COVID-19 pandemic disrupted the original design, and the control group could not be assessed after six months because most participants were unwilling to attend hospital visits during lockdowns. This means the analysis effectively became a single-arm before-and-after comparison, so some of the observed improvement could reflect natural variability, regression to the mean, or the motivating effect of increased attention. The sample was also small, dominated by men, and enrolled before newer heart failure drugs such as SGLT2 inhibitors became standard. These caveats temper the strength of the conclusions, though they do not erase the consistency of the physiological gains with the broader supervised-rehabilitation literature.

Even with those qualifications, the implications are considerable. Prior systematic reviews have found home-based cardiac rehabilitation to be non-inferior to center-based programs in clinical outcomes, with marginally higher completion rates, and the landmark HF-ACTION trial struggled to keep long-term adherence above 30 percent even with intensive support. Against that benchmark, an adherence rate above 90 percent in an unsupervised, home-delivered program is remarkable, and the authors suggest that simple tools such as pedometers, diaries, and weekly phone calls may offer a viable, cost-effective alternative to high-tech telemonitoring, especially in low-resource settings. For the vast majority of heart failure patients who never receive rehabilitation today, a program that requires little more than a pair of legs, a breathing device, a booklet, and a telephone line could bring the benefits of the clinic directly into the home.

Subject of Research: Home-based exercise and respiratory rehabilitation for chronic heart failure

Article Title: Beyond the clinic: a six-month home-based exercise and respiratory rehabilitation program improves functional capacity, respiratory muscle strength, and fatigue in chronic heart failure

Article References: Ciołkiewicz, M., Wojciuk, M., Kuryliszyn-Moskal, A., Dakowicz, A., Sawicka-Śmiarowska, E., & Kamiński, K. (2026). Beyond the clinic: a six-month home-based exercise and respiratory rehabilitation program improves functional capacity, respiratory muscle strength, and fatigue in chronic heart failure. Frontiers in Rehabilitation Sciences, 7, Article 1958027. https://doi.org/10.3389/fresc.2026.1958027

Image Credits: AI Generated

DOI: 10.3389/fresc.2026.1958027

Keywords: heart failure, cardiac rehabilitation, home-based exercise, respiratory muscle training, inspiratory muscle training, six-minute walk test, fatigue, functional capacity, HFrEF, adherence, telemonitoring, pilot study

The study, published as an open-access review in the journal Supportive Care in Cancer, evaluated the NUH Prehabilitation Service, a multimodal programme combining exercise, nutritional support and psychological preparation. Rather than offering the same package to everyone, the service follows a tiered, risk-stratified model endorsed by Macmillan Cancer Support, in which patients are allocated to one of three pathways according to clinical need. High-risk patients, identified using factors such as frailty, functional capacity, comorbidity and treatment complexity, were assigned to the Specialised pathway, attending supervised one-to-one or two-to-one exercise sessions with the hospital’s prehabilitation team up to three times a week. Lower-risk patients joined the Targeted pathway, attending community-based group classes led by an external provider that combined modified high-intensity interval training with strength exercises. A third group, the Universal pathway, received an individualised home exercise prescription with weekly check-ins for education and advice — an arms-length offer designed for patients who were already independently active or lived outside the immediate area.

The scale of the programme is striking. Of 1,961 patients referred over the 38-month period, 1,720 were included in the analysis, spanning seven surgical specialities including colorectal, gynaecological oncology, hepatopancreatobiliary, upper gastrointestinal, urology, head and neck, and thoracic surgery. That equates to an average of around 52 eligible referrals per month, a level of uptake the authors interpret as strong engagement from referring clinical teams. The cohort had a median age of 67 years, slightly more women than men, and nearly half were classified as obese. Colorectal surgery accounted for the largest share of participants at 38.5 per cent, followed by gynaecological oncology at 20.3 per cent.

To measure whether the programme worked, the team relied on validated functional and psychological instruments collected as part of routine clinical monitoring. Aerobic capacity was assessed with the Incremental Shuttle Walk Test, an externally paced protocol in which walking speed increases with each audio-cued level until the participant can no longer keep up. Lower-limb strength and endurance were measured with the 60-second sit-to-stand test, and grip strength was recorded with a hand-held dynamometer. Psychological well-being was tracked using two widely used self-report questionnaires: the Patient Health Questionnaire-9 for depression and the Generalised Anxiety Disorder-7 scale for anxiety. Self-reported weekly physical activity and the number of completed strength sessions rounded out the behavioural picture.

The results showed statistically significant improvements across every domain measured. On average, patients walked 57 metres further on the shuttle walk test after the programme, a gain with a moderate effect size that exceeds the minimal important differences of 35 to 53 metres typically reported for rehabilitation in long-term conditions. Sit-to-stand performance improved by six repetitions, roughly double or triple the threshold generally considered clinically meaningful. Depression scores fell by about two points, meeting the minimal clinically important difference established in UK primary care cohorts, while anxiety scores also decreased significantly. Perhaps most dramatically, self-reported weekly physical activity rose by 142 minutes — more than doubling — and the number of weekly strength sessions increased by 2.4, both with large effect sizes.

Importantly, these gains were not confined to the most intensive pathway. Although patients in the Specialised group showed greater improvements in depression scores compared with the Targeted group, and the Universal group increased strength sessions more than the Targeted group, most outcomes — including aerobic capacity, anxiety, grip strength and overall physical activity — showed no statistically significant differences between pathways. For the shuttle walk test, gains exceeded the minimal important difference in all three groups: 43 metres in Universal, 56 metres in Targeted and 64 metres in Specialised. The authors suggest this indicates that a tiered model can deliver meaningful benefit across all starting levels, and that even a low-intensity, arms-length offer may be a viable and scalable option for lower-risk patients when service capacity is constrained.

The findings align closely with other NHS prehabilitation programmes. The Greater Manchester Prehab4Cancer programme, one of the best-known community-based models, previously reported shuttle walk gains of around 50 metres and sit-to-stand improvements of 4.8 repetitions — figures comparable to those seen in Nottingham. The consistency across services strengthens the case that prehabilitation can be delivered at scale within publicly funded healthcare systems, not only in tightly controlled research trials. The Nottingham evaluation is also notable for reflecting routine clinical care rather than a research-driven intervention, which the authors argue enhances its real-world relevance and supports generalisation across a broad cancer population.

Not everything translated into clinically meaningful change. Although anxiety scores fell statistically significantly, from an average of about 6 to 4, the change fell short of the established minimal clinically important difference of four points on the GAD-7 scale, and baseline anxiety in this cohort was already low. The authors also note that research in oncology populations suggests the conventional GAD-7 threshold of 10 may underestimate anxiety in cancer patients, with better sensitivity at cut-offs of around 7 to 8, which calls for cautious interpretation of absolute scores. Depression, by contrast, showed a change that met the clinical significance threshold, and the greater improvement seen in the Specialised pathway hints that structured, individualised psychological support may add value over more generic delivery.

The evaluation is candid about its limitations. The analysis used a complete-case approach, excluding 241 patients with missing data, and assumes that data were missing completely at random — an assumption that, if wrong, could bias effect estimates. The observational design lacks randomisation, so causal inference is limited, and between-group comparisons were unadjusted for baseline differences and are therefore exploratory. Physical activity was self-reported, leaving results vulnerable to recall and social desirability bias. Selection bias may also operate upstream: referral depended on clinician discretion, tumour type and service capacity, and patients allocated to lower-intensity pathways may have been healthier or more motivated to begin with. Notably, the evaluation did not capture postoperative outcomes such as length of stay or complication rates, so it remains unknown whether the preoperative gains translated into downstream surgical benefits — a gap the authors flag as a priority for future data collection.

Engagement data reveal the practical friction points that any national rollout would need to address. A total of 8,250 service sessions were delivered, averaging 4.9 per patient, with median time in the service of 33.4 days — long enough, the authors note, to sit above the three-week threshold associated with improvements in postoperative complications, though benefits can begin to emerge within two weeks. Documented reasons for non-completion included short windows before surgery, non-attendance and discharge after assessment, often reflecting patient preference or a perception of already being fit enough. Reported barriers included travel distance, competing hospital appointments and caring responsibilities. Among 662 patients who completed a three-month postoperative questionnaire, 83.3 per cent agreed that prehabilitation helped them prepare for surgery and 61.1 per cent felt it supported their recovery — although only 31.2 per cent reported being more physically active afterwards, while 38.1 per cent felt less active, underscoring how difficult it is to sustain behaviour change through the surgical period itself.

The authors recommend several service improvements: routinely recording hospital length of stay to strengthen benchmarking and the health-economic case, and mitigating engagement barriers through hybrid delivery, digital follow-up and clearer clinician-led communication about the benefits of prehabilitation. They conclude that a multimodal, tiered prehabilitation service aligned with national guidance was linked to improvements in mood, strength and functional capacity, supporting patients’ surgical preparation and recovery, and that the findings justify integrating prehabilitation into routine cancer care. With 45 million cancer surgical procedures expected annually worldwide by 2030, and systematic reviews suggesting multimodal programmes may shorten hospital stays by around two days while proving cost-effective in a majority of economic evaluations, the Nottingham experience offers a template for how health systems might prepare a growing surgical population — not in the operating theatre, but in the crucial weeks before it.

Subject of Research: Multimodal prehabilitation before cancer surgery delivered through tiered NHS pathways

Article Title: Delivering prehabilitation in cancer surgery: a service evaluation at Nottingham University Hospitals

Article References: Alharbi, A., Haywood, A., & O’Connor, D. (2026). Delivering prehabilitation in cancer surgery: a service evaluation at Nottingham University Hospitals. Supportive Care in Cancer, 34(10), Article 973. https://doi.org/10.1007/s00520-026-11113-y

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11113-y

Keywords: prehabilitation, cancer surgery, NHS, exercise, risk stratification, functional capacity, depression, anxiety, physical activity, service evaluation, Nottingham University Hospitals, Supportive Care in Cancer

Specialized pro-resolving mediators, often abbreviated as SPMs, are lipid-derived signaling molecules that the body naturally produces to orchestrate the resolution of inflammation. Unlike anti-inflammatory drugs that broadly suppress immune activity, SPMs are thought to actively steer tissues from an inflammatory state back toward homeostasis, promoting clearance of debris and the return of normal cellular function. Because chronic, unresolved inflammation has been repeatedly implicated in the biology of long COVID, researchers hypothesized that boosting pro-resolving pathways with an SPM-enriched marine oil supplement might ease the persistent symptoms that plague patients. The idea is biologically plausible: omega-3 fatty acids such as eicosapentaenoic acid and docosahexaenoic acid serve as precursors for these mediators, and supplementing with concentrated fractions could, in theory, tip the inflammatory balance in a favorable direction.

The trial enrolled 144 adults with a mean age of 50 years, roughly 82 percent of whom were women, all experiencing post-COVID-19 condition lasting more than twelve weeks. The pronounced female predominance mirrors the epidemiology of the condition itself, which disproportionately affects women in midlife. Participants were randomized in a one-to-one ratio to receive either the SPM-enriched marine oil supplement or an identical placebo. Crucially, the study was triple-blind, meaning that participants, clinicians, and outcome assessors were all unaware of group assignment, minimizing bias in both treatment delivery and measurement. Every participant, regardless of supplement allocation, also completed a twelve-week asynchronous telerehabilitation program delivered through the HEFORA digital platform, allowing them to perform prescribed exercises at home on their own schedule.

The researchers chose health-related quality of life, measured with the widely used EQ-5D-5L instrument, as the primary outcome, reflecting the fact that long COVID is fundamentally a condition that degrades daily functioning rather than a single measurable physiological deficit. A battery of secondary outcomes captured the multidimensional nature of the syndrome: fatigue was quantified with the Fatigue Severity Scale, breathlessness with the Modified Medical Research Council dyspnea scale, respiratory muscle strength through maximal inspiratory and expiratory pressures, functional capacity with the six-minute walk test, and limb strength using thirty-second sit-to-stand and arm curl tests. Analyses followed an intention-to-treat approach, meaning every randomized participant was analyzed within their assigned group regardless of adherence, a method that preserves the randomization and gives the most conservative estimate of real-world effect.

After twelve weeks, the headline finding was a null one: there were no statistically significant differences between the supplement and placebo groups on any outcome, with all between-group comparisons yielding p-values above the conventional 0.05 threshold. In plain terms, adding the SPM-enriched supplement to telerehabilitation conferred no measurable advantage over telerehabilitation alone. For a field crowded with unproven remedies marketed to desperate patients, this kind of rigorous negative result carries real scientific value. It signals that, at least in this unselected population of long COVID patients and over a twelve-week window, simply supplying pro-resolving lipid mediators is not sufficient to accelerate recovery beyond what structured exercise and rehabilitation achieve on their own.

Yet the within-group results tell a more encouraging story. Both groups improved substantially across nearly every measure. Participants in the nutritional group walked an average of 37.82 meters farther on the six-minute walk test by the end of the program, a change that reached high statistical significance and that clinicians generally regard as meaningful for daily function. Quality of life scores rose, fatigue severity fell, and both limb strength and respiratory muscle pressures increased significantly. The placebo group showed a strikingly similar pattern of gains, with the sole exception of dyspnea, which did not improve significantly in that arm. The near-identical trajectories of the two groups reinforce the interpretation that the rehabilitation program itself, rather than the supplement, drove the observed recovery.

The trial’s exploratory adherence-stratified analyses added an intriguing wrinkle. When participants were sorted by how faithfully they followed the intervention, those with higher adherence displayed larger improvements than their less compliant counterparts. This pattern is consistent with a dose-response relationship for the rehabilitation component, but it also leaves open the possibility that the supplement might benefit a subset of highly engaged patients. The authors themselves are careful on this point: adherence-stratified analyses are exploratory and vulnerable to confounding, since people who adhere well to supplementation may also adhere better to exercise, sleep recommendations, and other health behaviors. The finding is best read as a hypothesis generator rather than evidence of efficacy.

The study’s design and funding deserve attention when weighing its conclusions. The trial was registered as NCT06063031 in September 2023, approved by the Ethics Committee of Aragón, and conducted with written informed consent under the Declaration of Helsinki. Funding came from the Government of Aragon through an industrial research call in the pharmaceutical sector, with the company SOLUTEX G.C. S.L. as beneficiary and the Aragón Health Research Institute subcontracted to manage the project. One author disclosed participation in the European project where the HEFORA platform was developed. These industry-linked arrangements are disclosed transparently, and the triple-blind, placebo-controlled architecture provides substantial protection against bias, but readers should nonetheless note the commercial interest in the tested product.

What does ARACOV-02 mean for the millions still struggling with long COVID? First, it strengthens the case for rehabilitation as a core intervention. A twelve-week, home-based, asynchronous telerehabilitation program produced measurable gains in walking distance, fatigue, quality of life, and respiratory and limb strength, all without requiring patients to travel to clinics, a significant advantage for a population whose symptoms often make travel exhausting. Telerehabilitation platforms like HEFORA could therefore extend evidence-based care to patients in rural areas or those too debilitated for in-person programs. Second, the trial tempers enthusiasm for SPM supplements as a general remedy, suggesting that unselected supplementation does not reliably outperform placebo in this heterogeneous patient population.

The authors point toward the next logical step: biomarker-guided studies that identify which phenotypes of post-COVID-19 condition, if any, are most likely to respond to pro-resolving nutritional strategies. Long COVID is almost certainly not a single disease but an umbrella term covering several mechanistically distinct subtypes, including those dominated by viral persistence, autoimmunity, dysautonomia, and unresolved inflammation. A supplement targeting inflammatory resolution might help the inflammatory subgroup while leaving others untouched, an effect that would be diluted to invisibility in an unstratified trial of 144 participants. Until such biomarker-driven trials are completed, patients and clinicians should view SPM supplementation for long COVID with measured skepticism, while taking genuine encouragement from the demonstrated power of structured, remotely delivered rehabilitation to restore function and quality of life.

Subject of Research: A randomized controlled trial of specialized pro-resolving mediators and telerehabilitation for post-COVID-19 condition

Article Title: Effects of specialized pro-resolving mediators and telerehabilitation on fatigue, dyspnea, and quality of life in post‑COVID‑19 condition: the ARACOV-02 randomized controlled trial

Article References: Carpallo-Porcar, B., Jiménez-Sánchez, C., Calvo, S., Kolesnyk-Sumskaya, E., Aller-Blanco, A. I., Gómez-Barrera, M., & del Corral Beamonte, E. (2026). Effects of specialized pro-resolving mediators and telerehabilitation on fatigue, dyspnea, and quality of life in post‑COVID‑19 condition: the ARACOV-02 randomized controlled trial. BMC Complementary Medicine and Therapies. https://doi.org/10.1186/s12906-026-05630-w

Image Credits: AI Generated

DOI: 10.1186/s12906-026-05630-w

Keywords: post-COVID-19 condition, long COVID, specialized pro-resolving mediators, telerehabilitation, randomized controlled trial, fatigue, dyspnea, quality of life, nutritional supplement, omega-3 fatty acids, functional capacity, respiratory muscle strength